Randomised study with ciprofloxacine in acute pancreatitis

A double-blind, placebo-controlled trial of ciprofloxacin prophylaxis in patients with acute necrotising pancreatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN75232398

Enrollment

Registered

2008-04-16

Start date

1999-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis Digestive System Acute pancreatitis

Interventions

All patients with acute pancreatitis suspected to have the severe form of the disease underwent a dynamic contrast-enhanced CT scanning within 48 - 72 hours of admission. When the CT showed a pancreat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All adult patients of either sex: 1. Without previous antibiotic treatment 2. With detectable pancreatic necrosis in a contrast-enhanced computed tomography (CT) scan 25 performed within 48 - 72 hours of admission

Exclusion criteria

Exclusion criteria: 1. Antibiotic allergy 2. Clinical evidence of sepsis on admission

Design outcomes

Primary

Measure	Time frame
To determine whether prophylaxis with intravenous ciprofloxacin could reduce the incidence of infected pancreatic necrosis.	—

Secondary

Measure	Time frame
Effects on: 1. Mortality rate 2. Extra-pancreatic infections 3. Surgical treatment, its timing and the re-operation rate 4. Development of organ failure 2 5. In-hospital as well as intensive care unit (ICU) length of stay	—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026